ArticleBMC microbiology2026
Rothia mucilaginosa alleviates constipation through gut microbiota remodeling and neuroactive pathway activation.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConstipation affects approximately 15% of the global population, and gut microbiota dysbiosis is implicated in its pathogenesis. Rothia mucilaginosa, a commensal bacterium with established anti-inflammatory properties in the respiratory tract, has not been investigated for its effects on intestinal function. This study aimed to evaluate the therapeutic potential of Rothia mucilaginosa in a constipation mouse model using multiomics approaches.
methodsLoperamide-induced constipation C57BL/6 mice (n = 26) were treated with Rothia mucilaginosa (2 × 10⁸ CFU/day). Therapeutic effects were assessed through fecal output parameters, gut microbiota restructuring (16S rRNA sequencing), functional genomic characterization (complete genome sequencing), host molecular responses (colon transcriptomics), and metabolic changes (untargeted metabolomics).
resultsRothia mucilaginosa intervention significantly improved fecal output in constipated mice. 16S rRNA sequencing revealed enrichment of beneficial bacteria including Akkermansia muciniphila and Alistipes finegoldii, while reducing pathobionts such as Escherichia coli. Genome analysis identified 194 functional genes related to short-chain fatty acid metabolism, vitamin biosynthesis, and gut colonization. Transcriptomic analysis revealed significant enrichment of the Neuroactive ligand-receptor interaction pathway with serotonin receptor Htr1b upregulation. Untargeted metabolomics identified 170 differential metabolites between intervention and model groups.
conclusionsRothia mucilaginosa alleviates constipation through beneficial microbiota remodeling and neuroactive pathway activation, supporting its potential as a candidate probiotic for clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.